Targeted drug extends survival of leukaemia patients
Washington: Patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments, experience long-term benefits when they switch to the targeted drug imatinib, according to a new study.
The finding indicates that imatinib is the treatment of choice for these patients.
Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and prognosis of patients with CML.
Now up to 93 percent of patients who take the drug as initial therapy for CML survive at least eight years, whereas prior to imatinib, patients survived an average of only three to six years.
While imatinib is now the standard drug given after a diagnosis of CML, approximately 15,000 to 20,000 patients in the United States may have started taking imatinib after failing to respond to the previous standard drug for CML, interferon.
Like patients who now take imatinib as initial therapy for their cancer, these patients seem to respond well to imatinib, at least in the short term; however, little is known about their long-term prognosis.
To investigate, Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center in Houston, and his colleagues analyzed 368 CML patients from their institution who started taking imatinib after failing to respond to interferon.
The team estimated that 68 percent of patients survived for at least 10 years. Previous research indicates that only 20 to 30 percent of patients who do not respond to interferon therapy and have no access to imatinib survive this long.
According to the authors, these findings suggest that most patients can benefit from imatinib after unsuccessful interferon treatments, and they do not have to consider other therapeutic options.
The study has been published online in Cancer, a peer-reviewed journal of the American Cancer Society.
More from India
More from World
More from Sports
More from Entertaiment
- Fresh plea in SC against triple talaq system
- Consumers will be compensated for unscheduled power cuts: Delhi CM Kejriwal
- Shocking! Man dies performing stunt in moving train in Mumbai
- China planning to stretch its Nepal rail link to Bihar: Report
- National child helpline number '1098' now launched in 25 languages!
- Mbose.in HSSLC 12th Results 2016: Meghalaya Board (megresults.nic.in) class 12th HSSLC Arts exam results 2016, MBOSE to be declared today on May 25 at 10 AM
- Uttarakhand board Class 10th results 2016 to be declared today on May 25, 2016 at 11 AM
- Goa GBSHSE SSC Class 10th Results 2016 to be declared today May 25, 2016 at 3 PM
- Uttarakhand board Class 12th results 2016 to be declared today on May 25, 2016 at 11 AM
- 'Russia killed 28,000 militants in Syria, third of all IS forces'